Showing 4821-4830 of 7240 results for "".
- GALDA Co-Director Explains Organization's Work and Impacthttps://practicaldermatology.com/news/GALDA-Co-Director-Explains-Organizations-Work-Impact/2475171/The Gay and Lesbian Dermatology Association (GALDA) is an organization of dermatologists and health-care professionals dedicated to unity and networking of the gay community at dermatology meetings. For Pride Month, we spoke with GALDA co-director William L Waller III, MD, FAAD, to learn more abo
- Skin Cancer Champions Launches New Sitehttps://practicaldermatology.com/news/Skin-Cancer-Champions-Launches-New-Site/2475125/Skin Cancer Champions announced the launch of a new website, skincancerchampions.org, aimed at making it easier for patients to find what they need, engage with resources, and help more people discover the community. “Our new site is a step forward in making our community more accessible,
- AB Chopra Epigenetics Launches With Plan to Revolutionize Longevityhttps://practicaldermatology.com/news/AB-Chopra-Epigenetics-Launches-With-Plan-Revolutionize-Longevity/2475124/Charles Rosier, co-founder of the Augustinus Bader skincare and biotech company, and Deepak Chopra, MD, announced the launch of AB Chopra Epigenetics, a revolutionary longevity platform that merges advanced artificial intelligence, epigenetic science, and consciousness-based healing to redefine t
- INTEGUMENT-INFANT to Test Roflumilast Cream in Children Under Twohttps://practicaldermatology.com/news/integument-infant-to-test-roflumilast-cream-in-children-under-two/2475087/Arcutis Biotherapeutics has announced the enrollment of the first participants in its new phase 2 INTEGUMENT-INFANT study focusing on the safety and tolerability of ZORYVE (roflumilast) cream 0.05% in infants with atopic dermatitis (AD).
- Patent Issued for Coya’s IL-2 Technologyhttps://practicaldermatology.com/news/patent-issued-for-coyas-il-2-technology/2474992/Coya Therapeutics has received a new U.S. patent for proprietary methods of producing a highly stable liquid formulation (aldesleukin) of recombinant human interleukin-2 (rhIL-2), according to a press release from the manufacturer.
- Zasocitinib Effective in TYK2 Inhibition for Inflammatory Skin Disease: Studyhttps://practicaldermatology.com/news/zasocitinib-effecgive-in-tyk2-inhibition-for-inflammatory-skin-disease/2474891/Zasocitinib, billed as a 'next-generation' therapy, showed pharmacologic potency and high specificity compared to Janus and other kinase inhibitors, according to new results published in the Journal of Investigative Dermatology</
- FDA Panel Urges Removal of Talc from Consumer Products Due to Cancer Linkhttps://practicaldermatology.com/news/fda-panel-urges-removal-of-talc-from-consumer-products-due-to-cancer-link/2474873/A U.S. Food and Drug Administration (FDA) advisory panel has reinforced longstanding concerns over the carcinogenic potential of talc, urging the agency to restrict its use in foods, drugs, and cosmetics. Citing more than thre
- Polypharmacy Issues in Older Patients Concerning but Improvinghttps://practicaldermatology.com/news/Polypharmacy-Issues-Older-Patients-Concerning-Improving/2474817/Geriatric medicine hinges on eight guiding principles, Freba Farhat, MD, said at the ElderDerm 2025 Conference in Washington, DC: life expectancy, multimorbidity, functional status, cognition, mobility, social support, patient preference, and polypharmacy. The last of those factors can sometimes
- ZORYVE Foam Cleared by FDA for Full-Body Psoriasishttps://practicaldermatology.com/news/zoryve-foam-cleared-by-fda-for-full-body-psoriasis/2474798/The US Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ ZORYVE® (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis in patients aged 12 and older, according to a press release from the manufacturer.
- Analysis Forecasts 140% Rise in Basal Cell Carcinoma by 2050https://practicaldermatology.com/news/analysis-forecasts-140-rise-in-basal-cell-carcinoma-by-2050/2474797/The global burden of skin cancer among adults aged 65 and older has increased steadily over the past three decades and is expected to continue rising through 2050, according to a new analysis of Global Burden of Disease (GBD) Study data.